HRP20100366T1 - Antagonisti receptora progesterona - Google Patents
Antagonisti receptora progesterona Download PDFInfo
- Publication number
- HRP20100366T1 HRP20100366T1 HR20100366T HRP20100366T HRP20100366T1 HR P20100366 T1 HRP20100366 T1 HR P20100366T1 HR 20100366 T HR20100366 T HR 20100366T HR P20100366 T HRP20100366 T HR P20100366T HR P20100366 T1 HRP20100366 T1 HR P20100366T1
- Authority
- HR
- Croatia
- Prior art keywords
- pentafluoro
- phenyl
- dien
- hydroxy
- pregna
- Prior art date
Links
- 229940123788 Progesterone receptor antagonist Drugs 0.000 title claims abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- -1 2,2-dimethylpropane -1,3-diyl Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006054535A DE102006054535A1 (de) | 2006-11-15 | 2006-11-15 | Progesteronrezeptorantagonisten |
| PCT/EP2007/009997 WO2008058767A1 (en) | 2006-11-15 | 2007-11-14 | Progesterone receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100366T1 true HRP20100366T1 (hr) | 2010-07-31 |
Family
ID=39243738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100366T HRP20100366T1 (hr) | 2006-11-15 | 2010-06-29 | Antagonisti receptora progesterona |
Country Status (41)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006054535A1 (de) | 2006-11-15 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Progesteronrezeptorantagonisten |
| EP2123279A1 (de) * | 2008-05-14 | 2009-11-25 | Bayer Schering Pharma Aktiengesellschaft | Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) * | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| US20130029953A1 (en) * | 2011-07-28 | 2013-01-31 | Klaus Nickisch | Progesterone antagonists |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US9096641B2 (en) | 2013-06-05 | 2015-08-04 | Evestra, Inc. | Imidazolyl progesterone antagonists |
| EP2868320A1 (de) | 2013-11-03 | 2015-05-06 | Flamina Holding AG | Zusammensetzung oder Gruppe von Zusammensetzungen zur Behandlung von menschlichen Zellen |
| CN113559075A (zh) | 2014-11-17 | 2021-10-29 | 康泰科思特生物制药公司 | 奥那司酮延长释放组合物和方法 |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
| EP3214092A1 (de) | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Prodrugs vom selektiven progesteronrezeptormodulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-on |
| JP2019513706A (ja) * | 2016-03-21 | 2019-05-30 | コンテキスト・バイオファーマ・インコーポレイテッド | オナプリストン代謝物質組成物及び方法 |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3347126A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| FR2596395B1 (fr) | 1986-03-26 | 1989-05-26 | Roussel Uclaf | Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| CN86102502B (zh) * | 1986-08-29 | 1988-06-22 | 上海市计划生育科学研究所 | 11，17位双取代δ4，9-雌甾二烯化合物的合成方法 |
| CA2100514C (en) | 1992-07-29 | 2005-03-29 | Johannes A. M. Hamersma | 17-spiromethylene steroids |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19535572B4 (de) * | 1994-09-14 | 2007-02-01 | Schering Ag | Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen |
| PT792152E (pt) | 1994-11-22 | 2004-07-30 | Balance Pharmaceuticals Inc | Metodos de contracepcao |
| WO1998005679A2 (en) | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19706061A1 (de) | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| US20010016578A1 (en) | 1997-06-18 | 2001-08-23 | Balance Pharmaceuticals, Inc. | Compositions and methods for contraception and for treatment of benign gynecological disorders |
| DE19929715A1 (de) * | 1999-06-24 | 2000-12-28 | Schering Ag | 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE10049736A1 (de) * | 2000-09-29 | 2002-04-18 | Jenapharm Gmbh | 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| WO2002032429A2 (en) * | 2000-10-18 | 2002-04-25 | Schering Aktiengesellschaft | Use of inhibitors of progesterone receptor for treating cancer |
| US20020143000A1 (en) | 2001-01-09 | 2002-10-03 | Christa Hegele-Hartung | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
| DE10221034A1 (de) | 2002-05-03 | 2003-11-20 | Schering Ag | 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ATE307823T1 (de) | 2002-05-03 | 2005-11-15 | Schering Ag | 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln |
| EP1862468A1 (de) * | 2006-06-02 | 2007-12-05 | Bayer Schering Pharma Aktiengesellschaft | Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on |
| DE102006054535A1 (de) | 2006-11-15 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Progesteronrezeptorantagonisten |
-
2006
- 2006-11-15 DE DE102006054535A patent/DE102006054535A1/de not_active Withdrawn
-
2007
- 2007-11-11 JO JO2007469A patent/JO2672B1/en active
- 2007-11-13 CL CL200703266A patent/CL2007003266A1/es unknown
- 2007-11-14 CN CN200780042476XA patent/CN101541823B/zh not_active Expired - Fee Related
- 2007-11-14 JP JP2009536670A patent/JP5260537B2/ja not_active Expired - Fee Related
- 2007-11-14 AT AT07819866T patent/ATE465169T1/de active
- 2007-11-14 EP EP07819866A patent/EP2081951B1/de active Active
- 2007-11-14 DE DE602007006040T patent/DE602007006040D1/de active Active
- 2007-11-14 WO PCT/EP2007/009997 patent/WO2008058767A1/en active Application Filing
- 2007-11-14 EA EA200900635A patent/EA017038B1/ru not_active IP Right Cessation
- 2007-11-14 PA PA20078755801A patent/PA8755801A1/es unknown
- 2007-11-14 CA CA2669767A patent/CA2669767C/en not_active Expired - Fee Related
- 2007-11-14 RS RSP-2010/0290A patent/RS51369B/en unknown
- 2007-11-14 AR ARP070105061A patent/AR063813A1/es unknown
- 2007-11-14 NZ NZ576927A patent/NZ576927A/en not_active IP Right Cessation
- 2007-11-14 PL PL07819866T patent/PL2081951T3/pl unknown
- 2007-11-14 DK DK07819866.0T patent/DK2081951T3/da active
- 2007-11-14 PE PE2007001568A patent/PE20081409A1/es not_active Application Discontinuation
- 2007-11-14 SI SI200730275T patent/SI2081951T1/sl unknown
- 2007-11-14 KR KR1020097012215A patent/KR101494914B1/ko not_active IP Right Cessation
- 2007-11-14 MX MX2009005212A patent/MX2009005212A/es active IP Right Grant
- 2007-11-14 PT PT07819866T patent/PT2081951E/pt unknown
- 2007-11-14 BR BRPI0718409-3A patent/BRPI0718409A2/pt not_active IP Right Cessation
- 2007-11-14 UA UAA200906032A patent/UA98312C2/ru unknown
- 2007-11-14 ES ES07819866T patent/ES2343915T3/es active Active
- 2007-11-14 AU AU2007321848A patent/AU2007321848B2/en not_active Ceased
- 2007-11-15 UY UY30718A patent/UY30718A1/es not_active Application Discontinuation
- 2007-11-15 TW TW096143300A patent/TW200831109A/zh unknown
- 2007-11-15 US US11/984,331 patent/US8053426B2/en not_active Expired - Fee Related
-
2009
- 2009-05-07 IL IL198650A patent/IL198650A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000185A patent/TN2009000185A1/fr unknown
- 2009-05-15 EC EC2009009337A patent/ECSP099337A/es unknown
- 2009-05-15 CO CO09050000A patent/CO6180443A2/es active IP Right Grant
- 2009-05-15 HN HN2009000997A patent/HN2009000997A/es unknown
- 2009-05-15 GT GT200900128A patent/GT200900128A/es unknown
- 2009-05-15 SV SV2009003260A patent/SV2009003260A/es active IP Right Grant
- 2009-06-12 NO NO20092284A patent/NO20092284L/no not_active Application Discontinuation
- 2009-06-12 ZA ZA2009/04150A patent/ZA200904150B/en unknown
- 2009-06-12 MA MA31988A patent/MA30990B1/fr unknown
-
2010
- 2010-03-22 HK HK10102964.6A patent/HK1136302A1/xx not_active IP Right Cessation
- 2010-06-29 HR HR20100366T patent/HRP20100366T1/hr unknown
- 2010-07-21 CY CY20101100681T patent/CY1110671T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100366T1 (hr) | Antagonisti receptora progesterona | |
| JP2010509386A5 (de) | ||
| US10238666B2 (en) | Pharmaceutical compositions and methods | |
| US8475804B2 (en) | Compositions and methods for treatment of filovirus-mediated diseases | |
| ES2671516T3 (es) | Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno | |
| RU2007101304A (ru) | Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение | |
| HRP20211124T1 (hr) | TETRAHIDRO-1H-PIRIDO[3,4-b]INDOL ANTI-ESTROGENI LIJEKOVI | |
| CA2611474C (en) | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| WO2008033466A2 (en) | Compositions and methods for treatment of viral diseases | |
| JP2011522822A5 (de) | ||
| EP2725902A2 (de) | Antivirale kombinationstherapie | |
| PE20060485A1 (es) | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| JP2005531488A5 (de) | ||
| UA101192C2 (uk) | Спосіб лікування раку молочної залози | |
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди | |
| CA3214530A1 (en) | Combination therapies using prmt5 inhibitors for the treatment of cancer | |
| JP2008516959A5 (de) | ||
| BRPI0417161A (pt) | compostos, composições farmacêuticas, e, uso de um composto | |
| RU2311408C2 (ru) | Производные аминотетралина в качестве антагонистов мускаринового рецептора | |
| CY1121190T1 (el) | Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης | |
| EA200501739A1 (ru) | Композиция, содержащая антагонисты рецептора прогестерона и чистые антиэстрогены, предназначенные для профилактики и лечения гормонзависимых заболеваний | |
| CA3006267C (en) | Estrogen receptor modulators | |
| ES2390911T3 (es) | Combinación de hormonas para aliviar los cambios anímicos dependientes del ciclo menstrual | |
| JP2016531886A (ja) | 全身性エリテマトーデス及び／または狼瘡腎炎の予防または治療のための方法 |